Compare CAPR & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | BGY |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 480.3M |
| IPO Year | 2011 | N/A |
| Metric | CAPR | BGY |
|---|---|---|
| Price | $7.60 | $4.93 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $27.25 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 298.4K |
| Earning Date | 11-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.41% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $5.10 |
| 52 Week High | $40.37 | $6.23 |
| Indicator | CAPR | BGY |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 28.28 |
| Support Level | $7.78 | N/A |
| Resistance Level | $10.62 | $5.85 |
| Average True Range (ATR) | 1.18 | 0.11 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 19.61 | 1.50 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.